Kissei Pharmaceutical Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Mutsuo Kanzawa

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	42.4yrs
CEO sahipliği	3.6%
Yönetim ortalama görev süresi	4.4yrs
Yönetim Kurulu ortalama görev süresi	9.4yrs

Son yönetim güncellemeleri

Recent updates

CEO

Mutsuo Kanzawa (75 yo)

42.4yrs

Görev süresi

Mr. Mutsuo Kanzawa is Chief Executive Officer of Kissei Pharmaceutical Co. Ltd and served as its President since June 1992. Mr. Kanzawa has been the Chairman of Kissei Pharmaceutical Co. Ltd. since June 20...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mutsuo Kanzawa	Chairman & CEO	no data	Veri yok	3.6% $ 37.1m
Yasuo Takehana	President	2.4yrs	Veri yok	0.038% $ 394.0k
Takahide Kitahara	GM of Financial Management Department	12.4yrs	Veri yok	0.021% $ 217.4k
Yoshio Furihata	Senior Advisor & Director	14.4yrs	Veri yok	0.030% $ 308.1k
Keiji Fukushima	Executive VP & Director	12.4yrs	Veri yok	0.028% $ 284.1k
Tetsu Takayama	Executive MD & Director	4.4yrs	Veri yok	0.037% $ 376.4k
Hiroshi Noake	GM of Pharmaceutical Sales Headquarters & Director	2.4yrs	Veri yok	0.0040% $ 40.9k
Keiji Miyazawa	GM of Research Division & Director	2.4yrs	Veri yok	0.0042% $ 43.4k

4.4yrs

Ortalama Görev Süresi

62.5yo

Ortalama Yaş

Deneyimli Yönetim: KSPH.F 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mutsuo Kanzawa	Chairman & CEO	42.4yrs	Veri yok	3.6% $ 37.1m
Yasuo Takehana	President	12.8yrs	Veri yok	0.038% $ 394.0k
Takahide Kitahara	GM of Financial Management Department	6.4yrs	Veri yok	0.021% $ 217.4k
Yoshio Furihata	Senior Advisor & Director	16.4yrs	Veri yok	0.030% $ 308.1k
Keiji Fukushima	Executive VP & Director	12.4yrs	Veri yok	0.028% $ 284.1k
Tetsu Takayama	Executive MD & Director	10.4yrs	Veri yok	0.037% $ 376.4k
Hiroshi Noake	GM of Pharmaceutical Sales Headquarters & Director	2.4yrs	Veri yok	0.0040% $ 40.9k
Keiji Miyazawa	GM of Research Division & Director	2.4yrs	Veri yok	0.0042% $ 43.4k
Shigetaka Shimizu	Independent Outside Director	10.4yrs	Veri yok	0.0089% $ 91.5k
Sayuri Uchikawa	Independent Outside Director	4.4yrs	Veri yok	0.0040% $ 40.9k
Minoru Nomura	Independent Outside Director	8.4yrs	Veri yok	0.012% $ 122.7k
Yoshinori Otsuki	Independent Outside Director	2.4yrs	Veri yok	0.0028% $ 28.9k

9.4yrs

Ortalama Görev Süresi

63.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: KSPH.F 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.4 yıldır).

Kissei Pharmaceutical Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

Recent updates

Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces an Equity Buyback for 1,400,000 shares, representing 3.17% for ¥5,292 million.

Kissei Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 05, 2024

Kissei Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 30, 2024

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024

Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 07, 2024

Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 2024

Kissei Pharmaceutical Co., Ltd. and Maruishi Pharmaceutical Co., Ltd. Announces KORSUVA®? IV Injection Syringe for Dialysis 17.5ug, 25.0ug to Launch in Japan for Treatment of Pruritus in Patients Undergoing Hemodialysis

Kissei Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Jan 30, 2024

Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2023

Kissei Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 07, 2023

Kissei Pharmaceutical Co., Ltd. Announces Withdrawal of Application for Marketing Approval for Rovatirelin for the Treatment of Spinocerebellar Degeneration in Japan

Kissei Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces an Equity Buyback for 2,000,000 shares, representing 4.34% for ¥6,000 million.

Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Kissei Pharmaceutical Co., Ltd. Receives Marketing Authorization Approval in Japan for TAVALISSE Tab. 100Mg and 150Mg, an Oral Spleen Tyrosine Kinase Inhibitor

Kissei Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Kissei Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter and Dividend Guidance for Year Ending of March 31, 2023, Payable Date on December 2, 2022

Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2022

Kissei Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 08, 2022

Kissei Pharmaceutical Co., Ltd. Provides Earning Guidance for the First Half Ending September 30, 2022 and Full Year Ending March 31, 2023

Kissei Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 10, 2022

Kissei Pharmaceutical Co., Ltd. Releases Positive Topline Results from Its Phase 3 Clinical Trial in Japan

Kissei Pharmaceutical Co., Ltd. announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan

Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 11, 2021

Kissei Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 01, 2021

Kissei Pharmaceutical Co., Ltd. to Report Q2, 2021 Results on Nov 15, 2020

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş